摘要
目的:探讨门冬氨酸鸟氨酸联合利福昔明治疗肝性脑病患者的临床效果及对神经症状的影响。方法:选取2018年9月-2020年9月来灯塔市中医医院就诊的156例肝性脑病患者,按照随机数字表法将患者分为对照组和研究组,每组78例。对照组使用门冬氨酸鸟氨酸治疗,研究组使用门冬氨酸鸟氨酸结合利福昔明治疗。比较两组疗效、数字连接试验(NCT)时间、神经功能评分[改良长谷川痴呆量表(HDS-R)、简易智力状态检查量表(MMSE)]及总胆红素(TBIL)、血氨、谷丙转氨酶(ALT)水平。结果:治疗后,两组NCT时间均短于治疗前,HDS-R、MMSE评分均高于治疗前,研究组NCT时间短于对照组,HDS-R、MMSE评分均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组TBIL、血氨、ALT水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。研究组总有效率高于对照组,差异有统计学意义(P<0.05)。结论:将门冬氨酸鸟氨酸结合利福昔明应用在肝性脑病患者治疗中,可起到一定的保护肝脏作用,明显改善患者神经症状,有效降低患者血氨,具有显著的治疗效果,值得临床推广。
Objective:To investigate the clinical effect of Ornithine Aspartate combined with Rifaximin in the treatment of hepatic encephalopathy and its influence on neurological symptoms.Method:A total of 156 patients with hepatic encephalopathy who came to Dengta Hospital of Traditional Chinese Medicine from September 2018 to September 2020 were selected,they were divided into control group and study group according to the random number table method,78 cases in each group.The control group was treated with Ornithine Aspartate,while the study group was treated with Ornithine Aspartate and Rifaximin.Efficacy,digital connection test (NCT) time,neurological function score[modified Hasegawa dementia scale (HDS-R),mini-mental state examination (MMSE)],total bilirubin (TBIL),serum ammonia,alanine aminotransferase (ALT) levels were compared between two groups.Result:After treatment,the NCT time of both groups were shorter than those before treatment,and the HDS-R and MMSE scores of both groups were higher than those before treatment,the NCT time of the study group was shorter than that of the control group,and the HDS-R and MMSE scores of the study group were higher than those of the control group,the differences were statistically significant (P<0.05).After treatment,the levels of TBIL,serum ammonia and ALT of both groups were lower than those before treatment,and those of the study group were lower than those of the control group,the differences were statistically significant (P<0.05).The total effective rate of the study group was higher than that of the control group,the difference was statistically significant (P<0.05).Conclusion:The application of Ornithine Aspartate combined with Rifaximin in the treatment of patients with hepatic encephalopathy can protect the liver,significantly improve patients’ neurological symptoms and effectively reduce patients’ serum ammonia,it has significant therapeutic effect and is worthy of clinical promotion.
作者
田宏伟
TIAN Hongwei(Dengta Hospital of Traditional Chinese Medicine,Liaoning Province,Dengta 111300,China)
出处
《中国医学创新》
CAS
2022年第9期18-21,共4页
Medical Innovation of China
关键词
血氨
肝功能
肝性脑病
利福昔明
门冬氨酸鸟氨酸
Serum ammonia
Liver function
Hepatic encephalopathy
Rifaximin
Ornithine Aspartate
作者简介
通信作者:田宏伟。
